Leprosy
Praveena J. Gunaratnam A , Warwick J. Britton B and Ann Hofmeyr C
+ Author Affiliations
- Author Affiliations
A NSW Public Health Officer Training Program, NSW Ministry of Health
B Centenary Institute of Cancer Medicine and Cell Biology
C Department of Clinical Infectious Diseases and Microbiology, Liverpool Hospital
NSW Public Health Bulletin 24(1) 50-50 https://doi.org/10.1071/NB12068
Published: 15 July 2013
References
[1] World Health Organization Leprosy Update 2011. Wkly Epidemiol Rec 2011; 86 389–99.| 21887885PubMed |
[2] Slaon-Gardner T, Stirzaker S, Knuckey D, Pennington K, Knope K, Fitzsimmons G, et al. Australia’s notifiable disease status 2009: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2011; 35 61–131.
[3] Rodrigues LC, Lockwood DNJ. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 2011; 11 464–70.
| Leprosy now: epidemiology, progress, challenges, and research gaps.Crossref | GoogleScholarGoogle Scholar | 21616456PubMed |
[4] Moet FJ, Pahan D, Oskam L, Richardus J. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ 2008; 336 761–4.
| Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial.Crossref | GoogleScholarGoogle Scholar | 18332051PubMed |
